Tourmaline Bio Operating Income

Tourmaline Bio posts a operating income of $-100M as of June 2025. That compares with $-44M in the prior-year period — down 131.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tourmaline Bio's operating income was $-44M. The latest reading is $-100M — a 131.2% year-over-year decrease (period ending June 2025). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Tourmaline Bio's financial statement story. At $-100M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TRML's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Tourmaline Bio's other metric pages and overview cover the third.

Judging Tourmaline Bio against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-100M here, then scan peer and history charts to see if the gap is persistent.